AGREEMENT BETWEEN CATALYST PHARMACEUTICAL PARTNERS, INC. AND THE DIVISION OF PHARMACOTHERAPIES AND MEDICAL CONSEQUENCES OF DRUG ABUSE NATIONAL INSTITUTE ON DRUG ABUSECollaboration Agreement • December 15th, 2010 • Catalyst Pharmaceutical Partners, Inc. • Pharmaceutical preparations • District of Columbia
This Agreement made this 7th day of April, 2010 by and between: Catalyst Pharmaceutical Partners, Inc. (hereafter referred to as “Collaborator”), a Delaware corporation, having its offices at 355 Alhambra Circle, Suite 1370, Coral Gables, FL 33134 and The Division of Pharmacotherapies and Medical Consequences of Drug Abuse (hereafter referred to as “DPMCDA”) of the National Institute on Drug Abuse (hereafter referred to as “NIDA”), a part of the National Institutes of Health (hereafter referred to as “NIH”) of the U.S. Public Health Services (hereafter referred to as “PHS”), Department of Health and Human Services (hereafter referred to as “DHHS”), an agency of the United States Government, having its offices at 6001 Executive Boulevard, Room 4123, MSC 9551, Bethesda, Maryland 20892.
